Show simple item record

Authordc.contributor.authorBarrientos Briones, Genaro 
Authordc.contributor.authorLlanos Vidal, Paola 
Authordc.contributor.authorBasualto-Alarcón, Carla 
Authordc.contributor.authorEstrada Hormazábal, Manuel 
Admission datedc.date.accessioned2020-07-09T20:31:11Z
Available datedc.date.available2020-07-09T20:31:11Z
Publication datedc.date.issued2020
Cita de ítemdc.identifier.citationFront Endocrinol. 2020; 11: 316es_ES
Identifierdc.identifier.other10.3389/fendo.2020.00316
Identifierdc.identifier.urihttps://repositorio.uchile.cl/handle/2250/175881
Abstractdc.description.abstractThe prevalence of cardiovascular mortality is higher in men than in age-matched premenopausal women. Gender differences are linked to circulating sex-related steroid hormone levels and their cardio-specific actions, which are critical factors involved in the prevalence and features of age-associated cardiovascular disease. In women, estrogens have been described as cardioprotective agents, while in men, testosterone is the main sex steroid hormone. The effects of testosterone as a metabolic regulator and cardioprotective agent in aging men are poorly understood. With advancing age, testosterone levels gradually decrease in men, an effect associated with increasing fat mass, decrease in lean body mass, dyslipidemia, insulin resistance and adjustment in energy substrate metabolism. Aging is associated with a decline in metabolism, characterized by modifications in cardiac function, excitation-contraction coupling, and lower efficacy to generate energy. Testosterone deficiency -as found in elderly men- rapidly becomes an epidemic condition, associated with prominent cardiometabolic disorders. Therefore, it is highly probable that senior men showing low testosterone levels will display symptoms of androgen deficiency, presenting an unfavorable metabolic profile and increased cardiovascular risk. Moreover, recent reports establish that testosterone replacement improves cardiomyocyte bioenergetics, increases glucose metabolism and reduces insulin resistance in elderly men. Thus, testosterone-related metabolic signaling and gene expression may constitute relevant therapeutic target for preventing, or treating, age- and gender-related cardiometabolic diseases in men. Here, we will discuss the impact of current evidence showing how cardiac metabolism is regulated by androgen levels in aging men.es_ES
Patrocinadordc.description.sponsorshipFondo Nacional de Ciencia y Tecnología (FONDECYT) Grant 1151118 1190406es_ES
Lenguagedc.language.isoenes_ES
Publisherdc.publisherFrontiers Mediaes_ES
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile*
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/*
Sourcedc.sourceFrontiers in Endocrinologyes_ES
Keywordsdc.subjectTestosteronees_ES
Keywordsdc.subjectCardiac diseaseses_ES
Keywordsdc.subjectAging menes_ES
Keywordsdc.subjectCardiac metabolismes_ES
Keywordsdc.subjectGlycolysises_ES
Keywordsdc.subjectAMPKes_ES
Keywordsdc.subjectPGC1 alphaes_ES
Keywordsdc.subjectSirtuinses_ES
Títulodc.titleAndrogen-regulated cardiac metabolism in aging menes_ES
Document typedc.typeArtículo de revistaes_ES
dcterms.accessRightsdcterms.accessRightsAcceso Abierto
Catalogueruchile.catalogadorctces_ES
Indexationuchile.indexArtículo de publicación ISI
Indexationuchile.indexArtículo de publicación SCOPUS


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Chile
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile